P2.10. Loss of EPHA2 Induces Primary Lorlatinib Resistance Through Sustained MAPK Activation - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Anlin Li
Meta Tag
Speaker Anlin Li
Topic Metastatic NSCLC: Targeted Therapy - FUSIONS
ALK tyrosine kinase inhibitors
primary resistance
ALK fusion positive lung cancer
genome-wide CRISPR screening
EPHA2 gene
MAPK signaling pathway
RAS oncogenic activity
Human GeCKOv2 CRISPR knockout pooled library
Lorlatinib sensitivity
dual-targeted therapy
Powered By